UK markets close in 3 hours 13 minutes

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
25.900.00 (0.00%)
As of 2:06PM CEST. Market open.
Full screen
Previous close25.90
Bid25.90 x 0
Ask26.16 x 0
Day's range25.78 - 26.50
52-week range22.02 - 109.10
Avg. volume207,536
Market cap905.262M
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Modified long-term share-based incentive program for 2021

    Orphazyme A/SCompany announcement No. 23/2021Company Registration No. 32266355 Copenhagen, Denmark, October 7, 2021 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 (the “LTIP”) with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the

  • Globe Newswire

    Orphazyme provides regulatory and financial updates

    Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C (NPC). The company also announces that it now expects to end 2021 with a cash position of no les

  • Business Wire

    Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, September 06, 2021--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired (1) Orphazyme American depositary shares ("ADSs") pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted